What is Daratumumab-lenalidomide-dexamethasone (DRd)?

Category: Prescription Drugs

false

See also: Daratumumab Dexamethasone Lenalidomide

Daratumumab-lenalidomide-dexamethasone (Drd), also known as DRd, is a regimen that may be used for the treatment of multiple myeloma. It includes daratumumab and lenalidomide, both of which are anticancer agents, and dexamethasone, a corticosteroid.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 2
Moderate 3
Mild 0
None 0

Commonly reported side effects and conditions associated with Daratumumab-lenalidomide-dexamethasone (DRd)

Side effect Patients Percentage
Fatigue 1
Peripheral neuropathy 1
Redness of skin (erythema) 1

Dosages

Based on patients currently taking Daratumumab-lenalidomide-dexamethasone (DRd)

Dosage Patients Percentage
daily 1

Why patients stopped taking Daratumumab-lenalidomide-dexamethasone (DRd)

Multiple reasons could be selected

Reason Patients Percentage
Side effects too severe 1
See 1 patient who's stopped taking Daratumumab-lenalidomide-dexamethasone (DRd)

Duration

Currently taking Daratumumab-lenalidomide-dexamethasone (DRd)

Duration Patients Percentage
6 months - 1 year 1

Stopped taking Daratumumab-lenalidomide-dexamethasone (DRd)

Duration Patients Percentage
6 months - 1 year 1
Adherence
Adherence Evaluations Percentage
Always 5
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 4
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 3
Not specified 2

What people switch to and from

Patients started taking Daratumumab-lenalidomide-dexamethasone (DRd) after stopping:

Treatment Patients Percentage
Carfilzomib (Kyprolis) 1

Patients stopped taking Daratumumab-lenalidomide-dexamethasone (DRd) and switched to:

Treatment Patients Percentage
Daratumumab (Darzalex) 1
Dexamethasone (Decadron) 1
Last updated:
There are no evaluations for Daratumumab-lenalidomide-dexamethasone (DRd).